Valuation : Genovis AB

Market Cap 1.38B 142M 122M 116M 105M 197M 13.57B 198M 529M 6.9B 533M 522M 21.81B P/E 2026 *
64.8x
P/E 2027 * 40.8x
Enterprise Value 1.27B 131M 112M 107M 96.55M 181M 12.47B 182M 487M 6.35B 490M 480M 20.05B EV / Sales 2026 *
8.59x
EV / Sales 2027 * 6.64x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.63%
1 week-2.39%
Current month-7.90%
1 month+2.93%
3 months+2.31%
6 months+22.30%
Current year-4.00%
1 week 20.3
Extreme 20.3
22.05
1 month 19
Extreme 19
22.8
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
25.65
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
90
10 years 2.1
Extreme 2.1
90
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 42 01/08/2026
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/05/26 Buy 4,146 0.0063%
24/02/26 Buy

Chief Financial Officer

3,137 0.0047%
24/02/26 Buy

Chief Financial Officer

2,470 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-2.63%-2.39%-12.63%-62.84% 142M
-1.04%-2.50%+177.10%+371.62% 21.13B
-1.68%-5.19%-39.31%-23.54% 9.62B
+3.33%+9.48%+425.19%+42.90% 8.94B
+1.25%-2.91%-28.85% - 6.88B
-0.14%-0.71%+82.31%+53.40% 6.54B
0.00%-6.45%-31.35%-24.13% 5.64B
-0.27%-2.60%-8.36%-20.94% 4.22B
-1.59%-9.17%+55.29%+67.99% 3.84B
-3.08%-5.58%-25.36%-32.60% 2.65B
Average -0.58%-2.82%+59.40%+41.32% 6.96B
Weighted average by Cap. -0.24%-2.02%+106.84%+132.34%

Financials

2026 *2027 *
Net sales 147M 15.2M 13.09M 12.4M 11.24M 21.08M 1.45B 21.19M 56.62M 739M 57.07M 55.82M 2.33B 185M 19.14M 16.49M 15.61M 14.15M 26.55M 1.83B 26.69M 71.31M 930M 71.88M 70.3M 2.94B
Net income 15.7M 1.62M 1.4M 1.32M 1.2M 2.25M 155M 2.26M 6.04M 78.75M 6.09M 5.95M 249M 33.6M 3.47M 2.99M 2.83M 2.56M 4.81M 331M 4.84M 12.92M 169M 13.02M 12.74M 533M
Net Debt -111M -11.46M -9.87M -9.35M -8.47M -15.89M -1.09B -15.97M -42.68M -557M -43.02M -42.08M -1.76B -145M -14.96M -12.89M -12.21M -11.07M -20.76M -1.43B -20.87M -55.76M -727M -56.2M -54.97M -2.3B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
11/09/26 SEK 20.40 -2.63% 50,813
10/09/26 SEK 20.95 +1.21% 28,944
09/09/26 SEK 20.70 -0.24% 210,822
08/09/26 SEK 20.75 -2.58% 192,004
07/09/26 SEK 21.30 +1.91% 170,476
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20.40SEK
Average target price
33.00SEK
Spread / Average Target
+61.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!